Kritoma

Discovery

Explore Topics Papers

Docs Terms Privacy

Search Kritoma

Recent searches

Searches you run from this bar will appear here.

GLP-1 receptor agonists for obesity treatment

Clinical MedicineUpdated Oct 5, 2026Version v1

Knowledge Timeline Gaps (1)Evidence (359)Community (0)

Evidence

Public papers linked to this topic and used as evidence for gaps, timelines, and knowledge views.

359 papers

SearchSort evidence

All359 Core251 Supporting111 Background0

Showing 85-96 of total 359 evidence records.

Open a paper to inspect abstract, source links, and topic context.

2026PubMedDirectly related

Molecular insights into GLP-1 receptor agonists and emerging metabolic-inflammatory targets in hidradenitis suppurativa.

Brogaard E; Nielsen VW; Pedersen NH; Thomsen SF

GLP-1 receptor agonists for obesity treatment — Research Evidence and Topic... | Kritoma

Jan 1, 2026

Expert opinion on therapeutic targets

2026PubMedDirectly related

Glucagon-like Peptide-1 Receptor Agonists Are Not Associated with Increased Risk of Acute Pancreatitis or Pancreatic Complications, Including Pancreatic Cancer, in Type 2 Diabetes: A Global Propensity-Matched Cohort Study.

Sun Y; Liu B; Loh H; Mathialagan S; Lin CH; Tarabichi Y; Veccia D; Wong R; Tse W; Song G

Jan 1, 2026Journal of personalized medicine

2026PubMedDirectly related

Cardiovascular outcomes associated With GLP-1 and dual GLP-1/GIP receptor agonists in patients with type 2 diabetes and inflammatory bowel disease: A retrospective real-world cohort study.

Kazi MAI; Mufarrih SM; Sirohi A; Hasan F; Sharma A; Singh S; Muganlinskaya N; Haq N

Jan 1, 2026PloS one

2026PubMedDirectly related

Clinical outcomes associated with glucagon-like peptide-1 receptor agonist therapy in patients with peripheral artery disease and diabetes.

Khadija HA; Alnees M; Abdullah A; Ibraheem K; Makhlouf TZ; Cohen R; Najajra D; Twito O; Schiller T; Kirzhner A

Jan 1, 2026Diabetes & metabolism

2026PubMedDirectly related

Estimating the carbon footprint of oral semaglutide (Rybelsus): a comparative analysis of the medicine carbon footprint model and manufacturer life-cycle assessment in pharmaceutical production.

Hansell L; Zhu W; Lynch M; Hocking SL; Celermajer DS; Sack F

Jan 1, 2026BMJ open

2026PubMedSupporting evidence

MASLD: Established Knowledge and Emerging Directions - Guideline Updates.

Roeb E; Geier A

Jan 1, 2026Zeitschrift fur Gastroenterologie

2026PubMedSupporting evidence

Meta-analysis and acupoint selection patterns of acupuncture for post-stroke foot drop.

Huang Y; Lin Y; Zheng B; Zhao X; Su Q; Wang Y; Ai J; Fu W; Lin C

Jan 1, 2026Frontiers in neurology

2026PubMedSupporting evidence

Association between abdominal obesity and cognitive outcomes in middle-aged adults: a systematic review.

Wang L; Cao Y; Wang Z; Xiong H; Xu Y; Ren J

Jan 1, 2026Frontiers in nutrition

2026PubMedSupporting evidence

Association between sleep-disordered breathing and liver outcomes in steatotic liver disease: a systematic review and meta-analysis.

Alhajery MA; Alotay AA

Jan 1, 2026Frontiers in medicine

2026PubMedSupporting evidence

Early scar-directed interventions for thyroidectomy scars: a systematic review and network meta-analysis.

Yu K; Hao Z; Sun J

Jan 1, 2026Frontiers in surgery

2026PubMedSupporting evidence

Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis.

Chen H; Wu X; Yuan M; Ren F; Liu T; Yang L; An X; Zhan Y

Jan 1, 2026Frontiers in endocrinology

2026PubMedSupporting evidence

Does More Speech Therapy Lead to Better Results in Childhood Apraxia of Speech? A Systematic Review and Meta-Analysis of the Available Evidence.

McCabe P; Thomas DC; Choo JXM; Heard R; Ng D

Jan 1, 2026International journal of language & communication disorders

Page 8 of 30Showing 85-96 of total 359 results.

1...789...30